🎥 At #EBMT25, Prof. Mohamad Mohty discussed the optimization of conditioning regimens for stem cell transplantation in AML and MDS.

Watch the interview here:
👉 buff.ly/G0iAVH1 👈

#BMTsm #AMLsm #Leusm #MDSsm #HemOnc #MedSky #HemeSky #BloodSky

At #EBMT25, Mattia Algeri provided valuable insights into considerations for selecting patients with transfusion-dependent #thalassemia for allogeneic transplant or gene therapy.

Watch the exclusive interview here:
👉 buff.ly/CetMOvd

#BMTsm #Hematology #BloodSky #MedSky #HemeSky

Infections are the leading cause of non-relapse mortality in patients undergoing #CARTCell therapy.💉🩸

Learn more about this topic from Eleftheria Kampouri, whom we had the pleasure of speaking with at the #EBMT25 meeting:

👉 buff.ly/mRcSnju

#ImmunoOnc #HemOnc #BloodSky #MedSky #HemeSky

#EBMT25 | The lovely Manuela Spadea speaks about work investigating letermovir prophylaxis versus pre-emptive therapy in pediatric patients and the impact on immune reconstitution after alloSCT.

Click to watch the interview:
👉 buff.ly/ymsLIT1

#BMTsm #HemOnc #MedSky #BloodSky #Hematology

"70% of patients with advanced systemic #Mastocytosis will have an SM component and an AHN component."

Hear as Deepti Radia discusses the diagnosis & management of SM with an associated hematologic neoplasm (AHN):

🎥 buff.ly/IjFJWyr

#MPNsm #HemOnc #EBMT25 #BloodSky #HemeSky #MedSky

The FT14 study is evaluating the safety & efficacy of fludarabine plus treosulfan as a conditioning regimen in patients with AML.

The lovely Vera Radici shares the interim results of this study in a recent interview from #EBMT25:

🎥 buff.ly/oiJdymd

#BMTsm #Leusm #AMLsm

At #EBMT25, Aldo Acosta-Medina shared insights into the clinical outcomes and treatment strategies for TA-TMA, outlining findings from the largest cohort of adult patients with TA-TMA to date!

Learn more by watching here:

👉 buff.ly/FPPGd6Z

#BMTsm #HemOnc #BloodSky #HemeSky #MedSky

#EBMT25 | The wonderful Prof. Anna Sureda shares insight into the current landscape of conditioning regimens for patients with #lymphoma undergoing autologous or allogeneic stem cell transplantation:

👉 buff.ly/wVsfCTg 👈

#LYMsm #BMTsm #HemOnc #HodgkinLymphoma

Responses With Compassionate Use of MDC-CAR-BCMA001 Support Further Study in R/R Myeloma and AL Amyloidosis Kiavasch Mohammad Nejad Farid, MD, discusses the signs of activity and safety with MDC-CAR-BCMA001 in pretreated patients with AL amyloidosis and myeloma.

Responses With Compassionate Use of MDC-CAR-BCMA001 Support Further Study in R/R Myeloma and AL Amyloidosis #EBMT25 #mmsm #hematology
www.onclive.com/view/respons...

Is there a preferable donor for alloSCT in patients with secondary AML in first complete remission?

Arnon Nagler commented on this at #EBMT25, highlighting the findings of a study of the ALWP:

🎥 buff.ly/1MAsXJG

#AMLsm #Leusm #BMTsm #HemOnc #MedSky #BloodSky #HemeSky

AlloSCT in advanced systemic #mastocytosis: who, when, and how? 🤔

These were all questions the lovely Deepti Radia answered in an interview at the recent #EBMT25 meeting!

Watch here for her valuable insight:

👉 buff.ly/XOYpBvQ 👈

#MPNsm #HemOnc #BMTsm #MedSky #BloodSky #HemeSky

QuANTUM-Wild: Quizartinib Phase 3 Trial in FLT3-ITD-Neg AML Phase 3 QuANTUM-Wild study tests quizartinib + chemo in FLT3-ITD-negative AML. Enrolling 700 patients for OS, safety, and more. EBMT 2025

QuANTUM-Wild: phase 3 trial enrolling per #EBMT25 abstract
sohoinsider.com/news/quantum...

Cilta-cel cuts death risk by 45% vs standard care in myeloma Cilta-cel cuts death risk by 45% vs standard care in myeloma, per CARTITUDE-4 study. OS, PFS, and QoL improved. EBMT 2025 results.

Nearly 3 years after treatment with cilta-cel, the risk of death was reduced by 45% compared with standard of care, according to long-term CARTITUDE-4 data #EBMT25

sohoinsider.com/news/cilta-c...

Want to hear about harnessing machine learning to predict outcomes post-alloSCT for patients with #myelofibrosis?🩸

We had the pleasure of catching up with Dr Adrian Mosquera-Orgueira at #EBMT25 to learn about this interesting topic!

Watch here:
🎥 buff.ly/7tAO9DJ

#MPNsm #MedSky #BloodSky #HemeSky

Don't miss our excellent interview from the #EBMT25 meeting in which Marion Subklewe speaks on the classification & management of hematotoxicity after #CARTCell therapy.

Watch here:
👉 buff.ly/fyjvhML 👈

#ImmunoOnc #HemOnc #Hematology #MedSky #BloodSky #HemeSky #HemeOnc

There are several important factors for physicians to consider when selecting a patient with aplastic anemia for transplantation.

Learn more from Juan Montoro in a recent interview:

👉 buff.ly/e86EdQO 👈

#Anemia #Hematology #BMTsm #EBMT25 #MedSky #BloodSky #HemeSky

Hear about advancements and promising strategies for the management of both acute and chronic #GvHD by watching our fantastic interview with Prof. Mohamad Mohty from #EBMT25! 🎥

Check it out here:
👉 buff.ly/l4g2cf2 👈

#BMTsm #HemOnc #BloodSky #HemeSky #MedSky #Hematology

Orca-T immunotherapy reduces GVHD over allogeneic HSCT Orca-T immunotherapy reduces GVHD over conventional allogeneic HSCT in leukemia and MDS patients according to phase 3 study.

Orca-T immunotherapy reduces GVHD over conventional allogeneic #HSCT #EBMT25
sohoinsider.com/news/orca-t-...

FELIX Analysis Suggests Consolidative SCT After Obe-Cel Does Not Improve EFS/OS in R/R B-ALL A small sample size from an analysis of the FELIX trial suggests consolidative SCT may not be needed after obe-cel treatment in relapsed/refractory B-ALL.

FELIX Analysis Suggests Consolidative SCT After Obe-Cel Does Not Improve EFS/OS in R/R B-ALL #EBMT25 #oncology

www.onclive.com/view/felix-a...

We want to say a huge thank you to the organizers of #EBMT25 for having us onsite at the meeting as media partners! 😄

We have already started sharing our exclusive content from the event, with lots more to come over the coming weeks – stay tuned! 🎥🩸

👉 buff.ly/D7CceUL

#HemOnc #BloodSky #HemeSky

What a great meeting #EBMT25 with a great and #ICOnic participation of Institut Català d’Oncología

Until the next one! See you in Madrid #EBMT26

Honored to present our latest #RomeeLab research on engineering IL-12-secreting CAR NK cells to target high-risk AML—demonstrating feasibility, safety, and efficacy.

What a pleasure to be at #EBMT25 in Florence! 🇮🇹🌞

ICANS, Corticosteroid Use Identified As Risk Factors for NRM-Associated Infections After Axi-Cel Infusion in R/R NHL Infections occur early after CAR T-cell therapy administration in patients with relapsed/refractory NHL.

ICANS, Corticosteroid Use Identified As Risk Factors for NRM-Associated Infections After Axi-Cel Infusion in R/R NHL #EBMT25 #lymsm #oncology www.onclive.com/view/icans-c...

Dive into the impactful work of GlobalBMT at @uicdom.bsky.social! Learn how by training & working alongside doctors from low & middle income countries, the program is helping to expand access to BMT across the globe. #EBMT25 youtu.be/CS0m_emarnU

Discover how the Metropolitan Transplant Network of Romagna, Italy, is revolutionizing patient care with advanced technology & collaborative efforts. Watch to learn more about their work now! #EBMT25 youtu.be/ko3Qe2lt1ok

Explore how Manning Family Children’s leads the way in pediatric care, offering advanced stem cell transplant programs to address health disparities in Louisiana & the Gulf South - ensuring that they're work makes a difference in children's lives. #EBMT25 youtu.be/qR75AJ9zvLc

Watch now as #EBMT25 attendees share their key takeaways, including the most impactful sessions & how the meeting has influenced their work & research. youtu.be/1b_ypONsFv4

Editor-in-chief @chadoc13.bsky.social discusses the 2nd edition of the EU CAR-T Handbook, highlighting key updates, emerging innovations & how it supports transplant professionals in delivering advanced cellular treatments. #EBMT25 youtu.be/MwYwDJfzKus

Graft-versus-host disease is a key focus for HSCT specialists, with ongoing research critical to improving management & understanding. Nurse Lynn Leppla & physicians Olaf Penack & Lars Klingen Gjærde share their insights now! #EBMT25 youtu.be/dCI4x2PyBz8

Watch as Nada Hamad & Sunil Bhat join EBMT TV to discuss the biggest barriers to HCT & cellular therapy access, from donor shortages to systemic challenges, & how solutions like international collaboration can help close the gap. #EBMT25 youtu.be/5PsXBMq0ydU